BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 21889558)

  • 1. Contacts with children and young people and adult risk of suffering herpes zoster.
    Salleras M; Domínguez A; Soldevila N; Prat A; Garrido P; Torner N; Borrás E; Salleras L
    Vaccine; 2011 Oct; 29(44):7602-5. PubMed ID: 21889558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Family history and herpes zoster risk in the era of shingles vaccination.
    Hernandez PO; Javed S; Mendoza N; Lapolla W; Hicks LD; Tyring SK
    J Clin Virol; 2011 Dec; 52(4):344-8. PubMed ID: 21924676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population.
    Tseng HF; Chi M; Smith N; Marcy SM; Sy LS; Jacobsen SJ
    J Infect Dis; 2012 Jul; 206(2):190-6. PubMed ID: 22669900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study.
    Thomas SL; Wheeler JG; Hall AJ
    Lancet; 2002 Aug; 360(9334):678-82. PubMed ID: 12241874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine.
    Tseng HF; Smith N; Sy LS; Jacobsen SJ
    Vaccine; 2011 May; 29(20):3628-32. PubMed ID: 21435407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Modelling the impact of vaccination on the epidemiology of varicella zoster virus].
    Bonmarin I; Santa-Olalla P; Lévy-Bruhl D
    Rev Epidemiol Sante Publique; 2008 Oct; 56(5):323-31. PubMed ID: 18951741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium.
    Bilcke J; Marais C; Ogunjimi B; Willem L; Hens N; Beutels P
    Vaccine; 2012 Jan; 30(3):675-84. PubMed ID: 22120193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Varicella zoster virus redux.
    Gelb LD
    Herpes; 2009 Jan; 15(3):62-3. PubMed ID: 19306605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoster vaccine: current status and future prospects.
    Oxman MN
    Clin Infect Dis; 2010 Jul; 51(2):197-213. PubMed ID: 20550454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.
    Mills R; Tyring SK; Levin MJ; Parrino J; Li X; Coll KE; Stek JE; Schlienger K; Chan IS; Silber JL
    Vaccine; 2010 Jun; 28(25):4204-9. PubMed ID: 20416263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chickenpox vaccines: new drugs. A favourable risk-benefit balance in some situations.
    Prescrire Int; 2005 Jun; 14(77):85-91. PubMed ID: 15977369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008.
    Lu PJ; Euler GL; Harpaz R
    Am J Prev Med; 2011 Feb; 40(2):e1-6. PubMed ID: 21238856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors.
    Lu PJ; Euler GL; Jumaan AO; Harpaz R
    Vaccine; 2009 Feb; 27(6):882-7. PubMed ID: 19071175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination.
    de Melker H; Berbers G; Hahné S; Rümke H; van den Hof S; de Wit A; Boot H
    Vaccine; 2006 May; 24(18):3946-52. PubMed ID: 16564115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No evidence of family history as a risk factor for herpes zoster in patients with post-herpetic neuralgia.
    Gatti A; Pica F; Boccia MT; De Antoni F; Sabato AF; Volpi A
    J Med Virol; 2010 May; 82(6):1007-11. PubMed ID: 20419815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prevention of herpes zoster by vaccination].
    Kofoed K; Rønholt F; Gerstoft J; Sand C
    Ugeskr Laeger; 2011 Jan; 173(2):110-4. PubMed ID: 21219841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Pellissier JM; Brisson M; Levin MJ
    Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Micronutrient intake and the risk of herpes zoster: a case-control study.
    Thomas SL; Wheeler JG; Hall AJ
    Int J Epidemiol; 2006 Apr; 35(2):307-14. PubMed ID: 16330478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination: a new option to reduce the burden of herpes zoster.
    Mick G
    Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination.
    Civen R; Chaves SS; Jumaan A; Wu H; Mascola L; Gargiullo P; Seward JF
    Pediatr Infect Dis J; 2009 Nov; 28(11):954-9. PubMed ID: 19536039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.